Clinical study of Jieyu Anshen Particles combined with paroxetine in treating senile coronary stable angina pectoris with depression

doi:10.3969/j.issn.1004-583X.2021.02.005

Abstract

Abstract:

Objective To observe clinical effects of Jieyu Anshen Particles combined with paroxetine in treating elderly patients with coronary stable angina pectoris and depression. Methods Eighty-six elderly patients with coronary stable angina pectoris complicated with depression were randomly divided into observation group and control group. The patients in control group was treated with drugs for coronary heart disease such as western medicine routine coronary artery expansion, antiplatelet aggregation, lipid regulation, and reduction of myocardial oxygen consumption, and then orally took paroxetine tablets with 20 mg/d. Based on the control group, the patients in observation group received Jieyu Anshen Particles and took each dose in 5 g in the morning and evening. The effiicacy, TCM syndrome scores, Hamilton Depression Scale(HAMD) scores and Self-rating Depression Scale(SDS) scores of patients in two groups before and after treatment were compared. Results The overall response rate of patients in observation group and control group was 88.10% and 68.29%, respectively(P<0.05). The scores of TCM symptoms, HAMD and SDS of patients in two groups were lower than before treatment (P<0.05), and the scores of observation group after treatment were lower than those of control group (P<0.05). Conclusion Jieyu Anshen Particles combined with paroxetine can not only improve the depression but also relieve the symptoms of coronary heart disease complicated with stable angina pectoris, and corresponding clinical effect is better than that of paroxetine alone, being worthy of promotion and application.

Key words: angina, stable, depression, Jieyu Anshen particles, paroxetine

CLC Number:

R541.4

Xie Bing, Zhao Fengfeng, Chen Liang. Clinical study of Jieyu Anshen Particles combined with paroxetine in treating senile coronary stable angina pectoris with depression[J]. Clinical Focus, 2021, 36(2): 121-124.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.005

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I2/121

Figures/Tables 3

References 21

[1]	北京高血压防治协会, 北京糖尿病防治协会, 北京慢性病防治与健康教育研究会, 等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志, 2020,12(8):1-73.
[2]	Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, et al. Ranolazine for stable angina pectoris[J]. Cochrane Database Syst Rev, 2017,2(2):1-149.
[3]	Goldberg JF, Siu C, Mao Y, et al. Major depressive disorder with mixed features and treatment response to lurasidone: a symptom network model[J]. J Affect Disord, 2020,277:1045-1054. doi: 10.1016/j.jad.2020.08.048 URL
[4]	Meijer A, Zuidersma M, de Jonge P. Depression as a non-causal variable risk marker in coronary heart disease[J]. BMC Med, 2013,11:130. doi: 10.1186/1741-7015-11-130 pmid: 23676144
[5]	邱红. 温阳益气方治疗冠心病慢性心力衰竭临床效果研究[J]. 中国医学创新, 2016,13(3):107-110.
[6]	国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志, 2018,10(6):1-130.
[7]	中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)[J]. 中华精神科杂志, 2001,34(3):59-63.
[8]	中医内科病证诊断疗效标准[J]. 辽宁中医药大学学报, 2016,18(7):32.
[9]	吴勉华, 王新月. 中医内科学[M].9版. 北京: 中国中医药出版社, 2012: 138.
[10]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 88-90.
[11]	中西医结合治疗冠心病心绞痛及心律失常座谈会. 冠心病心绞痛及心电图疗效评定标准[J]. 中国药事, 1987,1(2):17-20.
[12]	柴露露, 孙明月, 高蕊. 冠心病经PCI术后合并焦虑抑郁的中西医诊断与治疗研究进展[J]. 中西医结合心脑血管病杂志, 2019,17(3):375-378.
[13]	Rousan TA, Thadani U. Stable angina medical therapy management guidelines: a critical review of guidelines from the european society of cardiology and national institute for health and care excellence[J]. Eur Cardiol, 2019,14(1):18-22. doi: 10.15420/ecr.2018.26.1 pmid: 31131033
[14]	刘志学. 我国专家就心血管科就诊患者的心理处方达成共识[J]. 中国医药导报, 2013,10(31):132.
[15]	李江婵, 姚素华, 谢秀东, 等. 认知行为治疗对抑郁症患者病耻感和应对方式的影响研究[J]. 中国全科医学, 2015,18(4):463-465.
[16]	吕素英. 帕罗西汀联合米氮平治疗产后抑郁症的临床效果分析[J]. 中国实用神经疾病杂志, 2017,20(6):113-115.
[17]	王纯, 张宁, 张亚林, 等. 团体归因治疗与 5-羟色胺再摄取抑制剂治疗抑郁和焦虑症状的对照研究[J]. 中华精神科杂志, 2017,50(3):187-192.
[18]	贺文奇. 帕罗西汀治疗老年冠心病伴发抑郁症的临床特征探讨[J]. 中外医疗, 2015,34(31):113-114.
[19]	舒建中, 唐军, 李陈瑜, 等. 解郁安神颗粒合盐酸帕罗西汀片治疗缺血性脑中风后抑郁症的临床分析[J]. 中国实验方剂学杂志, 2016,22(13):177-181.
[20]	王泽凤, 李倩. 解郁安神颗粒联合氟西汀对精神分裂症伴抑郁认知功能的影响研究[J]. 中华中医药学刊, 2020,38(8):114-116.
[21]	赵连俊. 自拟解郁安神颗粒治疗脑卒中后抑郁的临床观察[J]. 中西医结合心脑血管病杂志, 2020,18(10):1623-1626.

组别	例数	显效 (例)	有效 (例)	无效 (例)	总有效率 [例(%)]
观察组	42	15	22	5	37(88.10)
对照组	41	9	19	13	28(68.29)
统计值			Z=-2.120		χ²=4.790
P值			0.034		0.028

组别	例数	显效 (例)	有效 (例)	无效 (例)	总有效率 [例(%)]
观察组	42	15	22	5	37(88.10)
对照组	41	9	19	13	28(68.29)
统计值			Z=-2.120		χ²=4.790
P值			0.034		0.028

组别	例数	干预前	干预后
观察组	42	24.19±3.46	13.40±5.17^*
对照组	41	23.95±3.86	16.41±5.38^*
t值		0.298	-2.599
P值		0.767	0.011

组别	例数	干预前	干预后
观察组	42	24.19±3.46	13.40±5.17^*
对照组	41	23.95±3.86	16.41±5.38^*
t值		0.298	-2.599
P值		0.767	0.011

组别	例数	HAMD		SDS
组别	例数	干预前	干预后	干预前	干预后
观察组	42	24.64±3.44	14.40±3.99^*	71.60±4.21	57.60±3.60^*
对照组	41	25.20±3.65	17.44±3.66^*	72.22±5.38	62.63±3.35^*
t值		-0.710	-3.605	-0.589	-6.593
P值		0.480	0.001	0.557	0.000